Welcome to our dedicated page for Exagen SEC filings (Ticker: XGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Exagen Inc. filings document formal disclosures for an autoimmune diagnostics company focused on AVISE-branded testing products. Current reports on Form 8-K furnish operating results and financial condition updates, including revenue, AVISE CTD test volume, average selling price, gross margin, operating expenses, net loss, adjusted EBITDA and cash measures.
Proxy materials cover annual meeting matters, board governance, committee membership, director elections, executive compensation and equity-award disclosures. Other 8-K filings record governance changes such as director departures, board size adjustments and committee assignments within Exagen’s public-company reporting framework.
EXAGEN Inc. Schedule 13G/A states that Jorey Chernett beneficially owned 2,413,901 shares of Common Stock as of the close of business on May 19, 2026. The filing says this represents 9.9% of the class, using 24,159,839 shares outstanding as of May 6, 2026 from the issuer's Form 10-Q. The filing lists the Reporting Person's principal business address in Bloomfield Hills, Michigan, and shows sole voting and dispositive power over the reported shares.
Exagen Inc. reported Q1 2026 revenue of $17.3 million, up from $15.5 million a year earlier, driven by higher AVISE® CTD test volumes and better average selling prices. AVISE® CTD accounted for about 91% of revenue.
The company posted a net loss of $4.0 million, slightly wider than Q1 2025, as operating expenses and interest costs increased. Gross profit rose to $10.2 million, producing a gross margin of about 59%.
Cash and cash equivalents were $21.5 million at March 31, 2026, with management stating this should fund obligations for at least 12 months, despite operating cash use of $10.4 million in the quarter. Long‑term borrowings, mainly the Perceptive Term Loan Facility, had a carrying value of $22.3 million, and warrant liability fell to $0.8 million as its fair value declined.
Exagen Inc. reported first quarter 2026 results showing record revenue and higher test pricing but continued losses. Revenue rose to $17.3 million, up 12% from 2025, with gross margin at 59.0%. AVISE CTD test volume grew 10% and trailing-twelve-month average selling price increased to $444 per test.
Net loss was $4.0 million, or $0.17 per share, slightly wider than a year ago, while adjusted EBITDA loss improved to $2.2 million. The company ended the quarter with $21.5 million in cash and cash equivalents and reaffirmed full-year 2026 revenue guidance of $70–73 million.
Exagen Inc. reported record revenue of $66.6 million for fiscal 2025 while advancing its AVISE® diagnostic platform and product pipeline. The company served over 137,000 patients with AVISE CTD, grew testing volume ~11%, expanded trailing twelve‑month ASP to $441 and finished the year with ~$32 million in cash. Management highlights commercial traction, new RA and T‑cell biomarkers, a growing pharma services backlog (~$4 million), and a stated path toward positive Adjusted EBITDA in the next 12–18 months.
Exagen Inc. is asking stockholders to vote at its 2026 Annual Meeting on June 9, 2026 in Carlsbad, California. Investors will elect two Class I directors for terms running to the 2029 meeting, ratify BDO USA, P.C. as auditor for 2026, and cast an advisory “say‑on‑pay” vote on executive compensation. Holders of 24,142,122 common shares as of April 15, 2026 may vote by phone, Internet, mail, or in person, with detailed instructions provided in the proxy materials. The proxy also outlines board structure, committee membership, governance practices, and provides full 2024–2025 compensation data for named executive officers.
Exagen Inc. reported that director Ana Hooker resigned from its Board of Directors, including all committee positions, effective April 17, 2026. She had served on the Audit Committee and as chair of the Nominating and Corporate Governance Committee. The company stated her resignation was not due to any disagreement regarding operations, policies, or practices.
Following her departure, the Board size was reduced from eight to seven members, and committee memberships were realigned among remaining directors.
EXAGEN INC. director Chas McKhann filed an amended Form 3 reporting his equity holdings. The filing lists a direct position of 7,500 Restricted Stock Units as of July 17, 2025. The entry reflects a holding record only, with no explicit buy or sell transaction indicated.
EXAGEN INC. director Chas McKhann has filed an initial ownership report on Form 3. The filing shows he holds 7,500 Restricted Stock Units, reported as directly owned. The entry is classified as a holding, with no buy or sell transactions reported in this filing.
Exagen Inc. Chief Financial Officer Jeffrey G. Black reported several equity-based compensation awards and a plan purchase. He received a stock option for 50,000 shares of common stock at $3.16 per share, expiring in 2036 and vesting over time, with potential full vesting upon certain change-in-control terminations.
He was also granted 75,000 restricted stock units, each representing one share of common stock, which vest in four equal annual installments starting on February 21, 2026, subject to continued service and similar change-in-control provisions. In addition, he acquired 1,511 shares of common stock at $3.077 per share through Exagen’s Employee Stock Purchase Plan. Following these grants and the ESPP purchase, he directly held 343,953 shares of common stock.
ABALLI JOHN reported acquisition or exercise transactions in this Form 4 filing.
EXAGEN INC. President and CEO John Aballi reported new equity compensation awards. He received stock options for 100,000 shares at $3.1600 per share, expiring on March 11, 2036, and a grant of 150,000 shares of common stock at no cost.
The 150,000-share award consists of restricted stock units that vest 25% on each of the first four anniversaries of February 21, 2026, with potential full vesting upon certain change-in-control terminations. The options vest 25% on February 21, 2027, then 1/48 of the total each month, with similar change-in-control protection.
After these awards, Aballi directly holds 839,834 shares of common stock and 175,000 stock options, and there are an additional 40,401 shares held indirectly by his spouse.